Endometrial Cancer Trial, Recruiting NCT06935305 Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT06935305
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with endometrial cancer confirmed through laboratory testing of tissue samples
  • People whose cancer appears to be at an early stage (Stage I or II) based on assessments done before surgery
  • People who are planned to undergo full surgical treatment to remove the cancer
  • People who are planned to have a sentinel lymph node mapping procedure attempted during surgery (a technique to check nearby lymph nodes for cancer spread)

Who may not be able to join:

  • People whose cancer is a type called uterine sarcoma, including a subtype known as endometrial stromal sarcoma
  • People who are having surgery that aims to preserve the ability to have children in the future
  • People whose cancer is classified as a "dedifferentiated" type (confirm with trial site)
  • People whose cancer is classified as an "undifferentiated" type (confirm with trial site)
  • People who have received treatment such as chemotherapy or radiation before surgery
  • People who have had previous surgery involving the lymph nodes in the pelvic area
  • People whose lymph nodes appear enlarged (greater than 15mm on the short side) on pre-surgery scans

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Francesco Fanfani, Professor, Fondazione Policlinico Agostino Gemelli IRCCS

Phone: +390630153421

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
30 July 2025
Est. completion
17 September 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Number of SLN metastasis detected by OSNA versus ultrastaging method

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov